AngioDynamics launches new 90 cm NeverTouch procedure kit for varicose veins

AngioDynamics (NASDAQ:ANGO) announced today the launch of the new 90 cm NeverTouch® procedure kit featuring a longer TRE-Sheath® introducer to gain vascular access above the ankle for the treatment of varicose veins that extend below the knee. The new kit complements existing kit lengths of 25 cm, 45 cm and 65 cm, and rounds out the NeverTouch fiber product offering.

"The NeverTouch fiber enhances the patient experience by reducing post-operative pain and bruising, and is now available in a 90 cm length to further enhance the physician's experience and increase the product's versatility," said Tom Kupec, Vice President of Marketing for AngioDynamics. "Our entire NeverTouch product offering now gives physicians the ability to tailor treatment to each patient's needs while still benefiting from the unique benefits of our gold-tip fiber."

Together with the 25 cm, 45 cm and 65 cm kit lengths, the new kit continues to build on the core benefits of the NeverTouch gold-tip laser fiber and VenaCure EVLT® system. The primary innovation in the NeverTouch tip is a glass weld at the distal tip of a 600 um fiber. The weld results in an effective fiber diameter of 905 ums and lowers the actual power density at the tip by 56% from that of a standard bare-tip 600 um fiber. This provides a homogeneous ablation with less focal charring of the vein wall that is typically seen with bare-tip fibers. The gold jacketed tip also maximizes tip visibility under ultrasound and eliminates chances of inadvertent fiber tip contact with the vein wall, further improving safety and patient comfort.

Source: AngioDynamics

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Spermidine regulates RIPK1 to combat diabetes and vascular damage